Color
blindness,
or color vision deficiency, is the inability or decreased ability to see color, or perceive color
differences, under normal lighting conditions. Color blindness affects a
significant percentage of the population .It is estimated to be over 250
million colour blind people worldwide and the
most common being red green color blindness. The effects of colour vision
deficiency can be mild, moderate or severe depending upon the defect. If a
person has inherited colour blindness, the condition will stay the same
throughout the life; it won’t get any better or worse.Now scientists have developed a lens that helps correct
color-blindness, allowing people to distinguish reds and greens they previously
couldn’t see, and glasses are called Oxy-Iso lenses.
Red-green colorblindness robs health care
professionals of the ability to see numerous symptoms. It can be practically
impossible for colour deficient, to see veins, vasculature, pallor, cyanosis,
jaundice, rashes, bruising, erythema, retinal damage, Ear and throat
inflammation, blood in excretions, and even medical charts and graphs. Oxy-Iso lenses
correct red-green color-deficiency in a manner consistent with the perceptual
needs of doctors, nurses and other medical personnel. They filter out certain wavelengths
of light and enhance others, primarily in the red part of the spectrum. It also hinders perception of concentration
variations, for this reason it is also used for vein-finding by medical
personnel with normal color vision.
INVASIVE CATHETER SYSTEM FOR MITRAL REGURGITATION
Mitral regurgitation (MR) is common worldwide and is
increasing in prevalence. As life expectancy increases, valvular heart disease
is becoming more common. Management of heart disease and primarily valvular
heart disease is expected to represent a significant proportion of healthcare
provided to the elderly population. MR
is due to the failure of anterior and posterior leaflet coaptation, leading to
a regurgitation of left ventricular blood into the left atrium in systole. The
standard of care for the treatment of significant MR is presently surgery.
Patients with MR who are not the candidates for surgery due
to risk of mortality have a need for treatment options that will reduce the
symptoms and improve the quality of life. So the scientists have developed a
device, which consists of implant catheters
and the MitraClip device. The device is a permanent implant that attaches to
the mitral valve leaflets. This procedure results in a double opening of the
mitral valve allowing greater closure and reduces the leakiness of the valve.
The device is inserted by a catheter through the femoral vein and guided into
the heart. The MitraClip device is positioned by grasping both leaflets of the
mitral valve. The MitraClip device is left in place and the delivery catheter
is removed.
The
MitraClip Delivery System is indicated for the percutaneous reduction of
significant symptomatic mitral regurgitation, due to primary abnormality of the
mitral apparatus, in patients who have been determined to be at prohibitive
risk for mitral valve surgery.
MEDICAL
DEVICE TO REDUCE FREQUENCY OF SEIZURE.
A chronic disorder characterized
by paroxysmal brain dysfunction due to excessive neuronal discharge, and
usually associated with some alteration of consciousness. People with epilepsy tend
to have recurrent seizures (fits). The seizures occur because of a sudden surge
of electrical activity in the brain - there is an overload of electrical
activity in the brain. Epilepsy affects over 50 million people worldwide and
approximately one third of these people have epilepsy that is not adequately
controlled by our present treatments.
The
U.S. Food and Drug Administration approved a device to help reduce the
frequency of seizures in epilepsy patients who have not responded well to
medications known as RNS System, which helps
reduce the frequency of seizures in epilepsy patients who have frequent,
disabling, partial-onset seizures and have not responded well to
medications. The RNS Stimulator consists
of a small neurostimulator implanted within the skull under the scalp. The
neurostimulator detects abnormal electrical activity in the brain and responds by delivering electrical
stimulation intended to normalize brain activity before the patient experiences
seizure symptoms.
The RNS System is intended to
interrupt brain activity before the patient experiences clinical seizures. It is used in conjunction with drugs in
individuals 18 years of age or older with partial onset seizures who have
undergone diagnostic testing to identify up to two areas of the brain where
seizures originate and have not responded to two or more antiepileptic
medications. The RNS System is used in patients who average three or more
disabling seizures per month. It has not been evaluated in patients with less
frequent seizures.
by Linu Mohan.P
Asst professor
No comments:
Post a Comment